P. Goeminne (Bornem, Belgium), A. Shoemark (Dundee (Angus), United Kingdom), W. Boersma (Alkmaar, Netherlands), M. Shteinberg (Haifa, Israel)
Adverse events during treatment of nontuberculous mycobacterial lung disease: do they really matter?
C. Balavoine (Tours, France), F. Blanc (Nantes, France), P. Lanotte (Tours, France), J. Meurice (Poitiers, France), C. Andrejak (Amiens, France), S. Marchand-Adam (Tours, France)
|  |
Peripheral blood eosinophilia and clinical phenotype in Bronchiectasis
H. Abo-Leyah (Dundee, United Kingdom), S. Finch (Dundee, United Kingdom), H. Keir (Dundee, United Kingdom), T. Fardon (Dundee, United Kingdom), J. Chalmers (Dundee, United Kingdom)
| |
Factors related to microbiological isolates in patients with Non Cystic-Fibrosis Bronquiectasis (Non-CFBQ)
J. Hernandez Borge (Badajoz, Spain), M. Benitez-Cano Gamonoso (Badajoz, Spain), M. Antona Rodriguez (Badajoz, Spain), M. Gomez Vizcaino (Badajoz, Spain), P. IñIgo Naranjo (Badajoz, Spain), P. Cordero Montero (Badajoz, Spain), A. Sanz Cabrera (Badajoz, Spain), J. Gutierrez Lara (Badajoz, Spain), L. Sierra Murillo (Badajoz, Spain), K. El Boutaibi Faiz (Badajoz, Spain), F. Marquez Perez (Badajoz, Spain)
|  |
Prognostic indicators of adult patients with non-CF bronchiectasis and those with combined COPD and non-CF bronchiectasis
G. Lynch (Bristol, United Kingdom), C. Mckerr (Bristol, United Kingdom), A. Massey (Bristol, United Kingdom), N. Jarad (Bristol, United Kingdom)
| |
Lung function decline in patients with bronchiectasis
A. Ikan (Haifa, Israel), Y. Adir (Haifa, Israel), N. Stein (Haifa, Israel), S. Schneer (Haifa, Israel), M. Shteinberg (Haifa, Israel)
| |
A randomised placebo-controlled dose finding study of tobramycin inhalation powder (TIP) in patients with bronchiectasis (BE) and pulmonary P. aeruginosa Pa) infection (iBEST-1)
M. Loebinger (London, United Kingdom), E. Polverino (Barcelona, Spain), F. Blasi (Milan, Italy), S. Elborn (London, United Kingdom), J. Chalmers (Dundee, United Kingdom), H. Tiddens (Rotterdam, Netherlands), H. Goossens (Antwerp, Belgium), M. Tunney (Belfast, United Kingdom), G. Angyalosi (Basel, Switzerland), A. Hill (Edinburgh, United Kingdom), C. Haworth (Cambridge, United Kingdom), . On Behalf Of The I Best-1 Trial Team (London, United Kingdom)
| |
Quality of life is associated with increased symptom burden and markers of disease severity: data from the German Bronchiectasis Registry PROGNOSIS
F. Ringshausen (Hannover, Germany), P. Sokol (Hannover, Germany), G. Barten (Hannover, Germany), A. De Roux (Berlin, Germany), R. Diel (Berlin, Germany), S. Konwert (Hannover, Germany), T. Welte (Hannover, Germany), M. Witte (Hannover, Germany), A. Zurawski (Hannover, Germany), J. Rademacher (Hannover, Germany)
| |
Paratracheal air cysts in patients with non-CF bronchiectasis
O. Munteanu (Chisinau, Republic of Moldova), I. Volosciuc (Chisinau, Republic of Moldova), D. Rusu (Chisinau, Republic of Moldova), E. Scutaru (Chisinau, Republic of Moldova), L. Onea (Chisinau, Republic of Moldova), V. Botnaru (Chisinau, Republic of Moldova)
| |
Validation of the Italian version of Bronchiectasis Quality of Life Questionnaire (QoL-B)
E. Franceschi (Milan, Italy), A. Bellofiore (Milan, Italy), C. Del Monaco (Milan, Italy), A. Gramegna (Milan, Italy), F. Nava (Milan, Italy), N. Borsa (Milan, Italy), F. Amati (Milan, Italy), M. Contarini (Milan, Italy), A. Quittner (Miami, United States of America), I. Baiardini (Genoa, Italy), S. Aliberti (Milan, Italy), F. Blasi (Milan, Italy)
| |
Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE)
E. Franceschi (Milan, Italy), S. Aliberti (Milan, Italy), F. Dente (Pisa, Italy), M. Berlendis (Brescia, Italy), E. De Juli (Milan, Italy), S. Battaglia (Palermo, Italy), A. Gramegna (Milan, Italy), F. Amati (Milan, Italy), M. Contarini (Milan, Italy), C. Calabrese (Naples, Italy), V. Conio (Pavia, Italy), V. Comellini (Bologna, Italy), N. Crimi (Catania, Italy), A. Corsico (Pavia, Italy), P. Faverio (Monza, Italy), S. Ferri (Catania, Italy), C. Galeone (Reggio Emilia, Italy), F. Menzella (Reggio Emilia, Italy), S. Nava (Bologna, Italy), P. Paggiaro (Pisa, Italy), N. Scichilone (Palermo, Italy), M. Dottorini (Perugia, Italy), R. Di Matteo (Perugia, Italy), M. Dodaj (Perugia, Italy), J. Chalmers (Dundee, United Kingdom), G. Sotgiu (Sassari, Italy), F. Blasi (Milan, Italy)
| |
Etiology, clinical, radiological and microbiological profile of patients with non-CF bronchiectasis in Pakistan.A single center study.
N. Sharif (Karachi, Pakistan), M. Saifullah (Karachi, Pakistan), N. Rao (Karachi, Pakistan)
| |
Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA)
J. Chalmers (Dundee, United Kingdom), B. Thompson (Owings Mills, MD , United States of America), J. Froehlich (Hayward, CA, United States of America), A. Davis (Research Triangle Park, NC, United States of America), J. Dahms (Hayward, CA, United States of America), D. Cipolla (Hayward, CA, United States of America), I. Gonda (Hayward, CA, United States of America)
| |
The heterogeneity of bronchiectasis patient characteristics, management and outcomes across Europe: Data from the EMBARC registry
J. Chalmers (Dundee, United Kingdom), E. Polverino (Barcelona, Spain), F. Blasi (Milan, Italy), F. Ringshausen (Hannover, Germany), A. De Soyza (Newcastle, United Kingdom), M. Vendrell (Girona, Spain), P. Goeminne (Belgium, Belgium), W. Boersma (Alkmaar, Netherlands), C. Haworth (Cambridge, United Kingdom), M. Murris (Hôpital Larrey-CHU de Toulouse, France), A. Hill (Edinburgh, United Kingdom), M. Loebinger (London, United Kingdom), R. Menendez (Valencia, Spain), A. Torres (Barcelona, Spain), K. Dimakou (Athens, Greece), T. Welte (Hannover, Germany), R. Wilson (London, United Kingdom), S. Elborn (London, United Kingdom), S. Aliberti (Milan, United Kingdom)
| |
ABPA screening in bronchiectasis: is there a grey zone?
P. Faverio (Monza, Italy), G. Bonaiti (Monza, Italy), A. Stainer (Monza, Italy), F. De Giacomi (Monza, Italy), S. Zucchetti (Monza, Italy), B. Bodini (Novara, Italy), F. Bini (Garbagnate Milanese, Italy), A. Pesci (Monza, Italy)
| |
Impact of Inflammatory bowel disease in bronchiectasis (IBD-BR) data from the EMBARC registry
A. De Soyza (Newcastle upon Tyne, United Kingdom), J. Chalmers (Dundee, United Kingdom), D. K (Athens, Greece), A. Hill (Edinburgh, United Kingdom), M. Loebinger (London, United Kingdom), R. Menendez (Valencia, Spain), F. Blasi (Milano, Italy), F. Ringshausen (Hannover, Germany), M. Vendrell (Girona, Spain), P. Goeminne (Leuven, Belgium), W. Boersma (MCA.NL, Netherlands), A. Torres (Bacelona, Republic of Korea), T. Welte (Hannover, Germany), R. Wilson (London, United Kingdom), C. Haworth (Cambs, United Kingdom), M. Murris (Toulouse, France), E. Polverino (Barcelona, Spain), S. Aliberti (Milano, Italy)
| |
Factors associated with the need of intravenous antibiotics in a cohort of adult patients with non-CF bronchiectasis
C. McKerr (Bristol, United Kingdom), A. Massey (Bristol, United Kingdom), G. Lynch (Bristol, United Kingdom), N. Jarad (Bristol, United Kingdom)
| |
Etiology of 1805 adult patients with bronchiectasis in western China
B. Liu (Chengdu, China), D. Wang (Chengdu, China), C. Liu (Chengdu, China), J. Luo (Chengdu, China), T. Huang (Chengdu, China), B. Liang (Chengdu, China), X. Wang (Chengdu, China), D. Yang (Chengdu, China)
| |
Cross-sectional comparison of the bronchiectasis-specific quality of life questionnaires
A. Spinou (London, United Kingdom), G. Housley (London, United Kingdom), S. Birring (London, United Kingdom), R. Wilson (London, United Kingdom), M. Loebinger (London, United Kingdom)
| |
Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections
A. O'Donnell (Washington, DC, United States of America), J. Froehlich (Hayward, CA, United States of America), B. Thompson (Owings Mills, MD, United States of America), J. Dahms (Hayward, CA, United States of America), D. Cipolla (Hayward, CA, United States of America), A. Davis (Research Triangle Park, NC, United States of America), I. Gonda (Hayward, CA, United States of America), C. Haworth (Cambridge, United Kingdom)
| |
Is there a relationship between adventitious respiratory sounds and disease severity in patients with bronchiectasis? A cross-sectional study.
I. Tobajas-Sagaste (Zaragoza, Spain), M. Francín-Gallego (Zaragoza, Spain), M. San Miguel-Pagola (Zaragoza, Spain), J. Saez-Perez (Zaragoza, Spain), B. Herrero Cortina (Zaragoza, Spain)
| |